MIF synergizes with trypanosoma cruzi antigens to promote efficient dendritic cell maturation and IL-12 production via p38 MAPK

International Journal of Biological Sciences

Volumn 7, Issue 9, 2011, Pages 1298-1310

  Terrazas, Cesar A ^a   Huitron, EriK ^a   Vazquez, Alicia ^a   Juarez, Imelda ^a   Camacho, Griselda M ^a   Calleja, Elsa A ^a   Rodriguez Sosa, Miriam ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Dendritic cells; ERK1 2 MAPK; Macrophage migration inhibitory factor; Macrophages; p38 MAPK; Trypanosoma cruzi

Indexed keywords

MUS; TRYPANOSOMA CRUZI;

EID: 81255189056     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.1298     Document Type: Article

References (76)

1. Miles M. A, Llewellyn M. S, Lewis M. D, et al. The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future. Parasitology. 2009; 136(12): 1509-28.
2. Coura J. R, and Dias J.C. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Os-waldo Cruz. 2009; 104(Suppl 1): 31-40.
3. Ocana-Mayorga S, Llewellyn M. S, Costales J. A, et al. Sex, sub-division, and domestic dispersal of Trypanosoma cruzi lineage I in southern Ecuador. PLoS Negl Trop Dis. 2010; 4(12): e915.
4. Parker E. R, and Sethi A. Chagas disease: coming to a place near you. Dermatol Clin. 2011; 29(1): 53-62.
5. Junqueira C, Caetano B, Bartholomeu D. C, et al. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med. 2010; 15(12): e29.
6. Rodrigues C. M, Valadares H. M, Francisco A. F, et al. Coinfec-tion with different Trypanosoma cruzi strains interferes with the host immune response to infection. PLoS Negl Trop Dis. 2010; 4(10): e846.
7. Maya J. D, Orellana M, Ferreira J, et al. Chagas disease: Present status of pathogenic mechanisms and chemotherapy. Biol Res. 2010; 43(3): 323-31.
8. Parodi C, Padilla A.M., and Basombrio M.A. Protective im-munity against Trypanosoma cruzi. Mem Inst Oswaldo Cruz. 2009; 104(Suppl 1): 288-94.
9. Sathler-Avelar R, Vitelli-Avelar D. M, Teixeira-Carvalho A, et al. Innate immunity and regulatory T-cells in human Chagas dis-ease: what must be understood? Mem Inst Oswaldo Cruz. 2009; 104(Suppl 1): 246-51.
10. Dosreis G.A. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res. 2011; 44(2): 84-90.
11. Gutierrez F. R, Guedes P. M, Gazzinelli R. T, et al. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol. 2009; 31(11): 673-85.
12. Poncini C. V, Gimenez G, Pontillo C. A, et al. Central role of extracellular signal-regulated kinase and Toll-like receptor 4 in IL-10 production in regulatory dendritic cells induced by Trypanosoma cruzi. Mol Immunol. 2010; 47(11-12): 1981-8.
13. Kuehn C. C, Oliveira L. G, Santos C. D, et al. Prior and concomi-tant dehydroepiandrosterone treatment affects immunologic response of cultured macrophages infected with Trypanosoma cruzi in vitro? Vet Parasitol. 2011; 177(3-4): 242-6.
14. Marinho C. R, Nunez-Apaza L. N, Martins-Santos R, et al. IFN-gamma, but not nitric oxide or specific IgG, is essential for the in vivo control of low-virulence Sylvio X10/4 Trypanosoma cruzi parasites. Scand J Immunol.2007; 66(2-3): 297-308.
15. Michailowsky V, Silva N. M, Rocha C. D, et al. Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Am J Pathol. 2001; 159(5): 1723-33.
16. Silva J. S, Machado F.S., and Martins G.A. The role of nitric oxide in the pathogenesis of Chagas disease. Front Biosc.2003; 8: s314-25.
17. Gutierrez F. R, Mineo T. W, Pavanelli W. R, et al. The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz. 2009; 104(Suppl 1): 236-45.
18. Laucella S. A, Rottenberg M.E., and de Titto E.H. Role of cyto-kines in resistance and pathology in Trypanosoma cruzi infec-tion. Rev Argent Microbiol. 1996; 28(2): 99-109.
19. Abrahamsohn I. A, and Coffman R.L. Trypanosoma cruzi: IL-10 TNF, IFN-gamma, and IL-12 regulate innate and acquired im-munity to infection. Exp Parasitol. 1996; 84(2): 231-44.
20. Awandare G. A, Ouma C, Keller C. C, et al. A macrophage mi-gration inhibitory factor promoter polymorphism is associated with high-density parasitemia in children with malaria. Genes Immun. 2006; 7(7): 568-75.
21. Amaral F. A, Fagundes C. T, Guabiraba R, et al. The role of macrophage migration inhibitory factor in the cascade of events leading to reperfusion-induced inflammatory injury and le-thality. Am J Pathol. 2007; 171(6): 1887-93.
22. Terrazas C. A, Juarez I, Terrazas L. I, et al. Toxoplasma gondii: impaired maturation and pro-inflammatory response of den-dritic cells in MIF-deficient mice favors susceptibility to infec-tion. Exp Parasitol. 2010; 126(3): 348-58.
23. Popa C, van Lieshout A. W, Roelofs M. F, et al. MIF production by dendritic cells is differentially regulated by Toll-like recep-tors and increased during rheumatoid arthritis. Cytokine. 2006; 36(1-2): 51-6.
24. Cooke G, Armstrong M.E., and Donnelly S.C. Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. Biofactors. 2009; 35(2): 165-8.
25. Xin D, Rendon B. E, Zhao M, et al. The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through beta-catenin-dependent and-independent mecha-nisms. Mol Cancer Res, 2010. 8(12): 1601-9.
26. Balachandran S, Gadekar P. K, Parkale S, et al. Synthesis and biological activity of novel MIF antagonists. Bioorg Med Chem Lett. 2011; 21(5): 1508-11.
27. Roger T, David J, Glauser M. P, et al. MIF regulates innate im-mune responses through modulation of Toll-like receptor 4. Nature. 2001; 414(6866): 920-4.
28. Calandra T, Echtenacher B, Roy D. L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med. 2000; 6(2): 164-70.
29. Reyes J. L, Terrazas L. I, Espinoza B, et al. Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection. Infect Immun. 2006; 74(6): 3170-9.
30. Juttner S, Bernhagen J, Metz C. N, et al. Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endoge-nous TNF-alpha. J Immunol. 1998; 161(5): 2383-90.
31. Fan H, Hall P, Santos L. L, et al. Macrophage migration inhibi-tory factor and CD74 regulate macrophage chemotactic re-sponses via MAPK and Rho GTPase. J Immunol. 2011; 186(8): 4915-24.
32. Toh M. L, Aeberli D, Lacey D, et al. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol. 2006; 177(7): 4818-25.
33. Aeberli D, Yang Y, Mansell A, et al. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett. 2006; 580(3): 974-81.
34. Santos L. L, Dacumos A, Yamana J, et al. Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clin Exp Immunol. 2008; 152(2): 372-80.
35. Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008; 283(5): 2784-92.
36. Lue H, Thiele M, Franz J, et al. Macrophage migration inhibi-tory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007; 26(35): 5046-59.
37. Bozza M, Satoskar A. R, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999; 189(2): 341-6.
38. Espinoza B, Rico T, Sosa S, et al. Mexican Trypanosoma cruzi T. cruzi I strains with different degrees of virulence induce diverse humoral and cellular immune responses in a murine experimental infection model. J Biomed Biotechnol. 2010;:890672.
39. Lowry O. H, Rosebrough N. J, Farr A. L, et al. Protein measure-ment with the Folin phenol reagent. J Biol Chem. 1951; 193(1): 265-75.
40. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supple-mented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992; 176(6): 1693-702.
41. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999; 1(2): 94-7.
42. Dong C, Davis R.J., and Flavell R.A. MAP kinases in the im-mune response. Annu Rev Immunol. 2002; 20: 55-72.
43. Qian C, Jiang X, An H, et al. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood. 2006; 108(7): 2307-15.
44. Park S. J, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Im-munol. 2004; 173(6): 3844-54.
45. Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce dis-tinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol. 2003; 171(10): 4984-9.
46. Jackson A. M, Mulcahy L. A, Porte J, et al. Role of mito-gen-activated protein kinase and PI3K pathways in the regula-tion of IL-12-family cytokines in dendritic cells and the genera-tion of T H-responses. Eur Cytokine Netw. 2010; 21(4): 319-28.
47. Steinman R. M, Hawiger D, Liu K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci. 2003; 987: 15-25.
48. Terrazas C. A, Terrazas L.I., and Gomez-Garcia L. Modulation of dendritic cell responses by parasites: a common strategy to survive. J Biomed Biotechnol. 2010;:357106.
49. Lanzavecchia A, and Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science. 2000; 290(5489): 92-7.
50. Manickasingham S. P, Edwards A. D, Schulz O, et al. The ability of murine dendritic cell subsets to direct T helper cell differen-tiation is dependent on microbial signals. Eur J Immunol. 2003; 33(1): 101-7.
51. Almeida I. C, and Gazzinelli R.T. Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypano-soma cruzi: structural and functional analyses. J Leukoc Biol. 2001; 70(4): 467-77.
52. Ouaissi A, Guilvard E, Delneste Y, et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell mat-uration, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol. 2002; 168(12): 6366-74.
53. Campos M. A, Almeida I. C, Takeuchi O, et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol. 2001; 167(1): 416-23.
54. Oliveira A. C, Peixoto J. R, de Arruda L. B, et al. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher re-sistance to infection with T. cruzi. J Immunol. 2004; 173(9): 5688-96.
55. Ropert C, Almeida I. C, Closel M, et al. Requirement of mito-gen-activated protein kinases and I kappa B phosphorylation for induction of proinflammatory cytokines synthesis by mac-rophages indicates functional similarity of receptors triggered by glycosylphosphatidylinositol anchors from parasitic proto-zoa and bacterial lipopolysaccharide. J Immunol. 2001; 166(5): 3423-31.
56. Bafica A, Santiago H. C, Goldszmid R, et al. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol. 2006; 177(6): 3515-9.
57. Ropert C, and Gazzinelli R.T. Regulatory role of Toll-like re-ceptor 2 during infection with Trypanosoma cruzi. J Endotoxin Res. 2004; 10(6): 425-30.
58. Belaunzaran M. L, Wainszelbaum M. J, Lammel E. M, et al. Phospholipase A1 from Trypanosoma cruzi infective stages generates lipid messengers that activate host cell protein kinase c. Parasitology. 2007; 134(Pt 4): 491-502.
59. Alba Soto C. D, Mirkin G. A, Solana M. E, et al. Trypanosoma cruzi infection modulates in vivo expression of major histo-compatibility complex class II molecules on antigen-presenting cells and T-cell stimulatory activity of dendritic cells in a strain-dependent manner. Infect Immun. 2003; 71(3): 1194-9.
60. Van Overtvelt L, Vanderheyde N, Verhasselt V, et al. Trypa-nosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines HLA-DR, and costimulatory molecules. Infect Immun. 1999; 67(8): 4033-40.
61. Brodskyn C, Patricio J, Oliveira R, et al. Glycoinositolphospho-lipids from Trypanosoma cruzi interfere with macrophages and dendritic cell responses. Infect Immun. 2002; 70(7): 3736-43.
62. Chaussabel D, Pajak B, Vercruysse V, et al. Alteration of migra-tion and maturation of dendritic cells and T-cell depletion in the course of experimental Trypanosoma cruzi infection. Lab In-vest. 2003; 83(9): 1373-82.
63. Vray B, Camby I, Vercruysse V, et al. Up-regulation of galec-tin-3 and its ligands by Trypanosoma cruzi infection with modulation of adhesion and migration of murine dendritic cells. Glycobiology. 2004; 14(7): 647-57.
64. Poncini C. V, Alba Soto C. D, Batalla E, et al. Trypanosoma cruzi induces regulatory dendritic cells in vitro. Infect Immun. 2008; 76(6): 2633-41;
65. Leng L, Metz C. N, Fang Y, et al. MIF signal transduction initi-ated by binding to CD74. J Exp Med. 2003; 197(11): 1467-76.
66. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007; 13(5): 587-96.
67. Ortolano S, Hwang I. Y, Han S. B, et al. Roles for phosphoinosi-tide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol. 2006; 36(5): 1285-95.
68. Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macro-phage migration-inhibitory factor-and CD74-dependent man-ner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A. 2007; 104(33): 13408-13.
69. Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006; 25(4): 595-606.
70. Mitchell R. A, Metz C. N, Peng T, et al. Sustained mito-gen-activated protein kinase (MAPK) and cytoplasmic phos-pholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocor-ticoid action. J Biol Chem. 1999; 274(25): 18100-6.
71. Yu X, Lin S. G, Huang X. R, et al. Macrophage migration inhibi-tory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J Interferon Cytokine Res. 2007; 27(2): 103-9.
72. Pakozdi A, Amin M. A, Haas C. S, et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther. 2006; 8(4): R132.
73. Lin X, Sakuragi T, Metz C. N, et al. Macrophage migration in-hibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis. Shock. 2005; 24(6): 556-63.
74. Coleman A. M, Rendon B. E, Zhao M, et al. Cooperative regula-tion of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol. 2008; 181(4): 2330-7.
75. Qi D, Hu X, Wu X, et al. Cardiac macrophage migration inhib-itory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. J Clin Invest. 2009; 119(12): 3807-16.
76. Kleemann R, Hausser A, Geiger G, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000; 408(6809): 211-6.